Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Arezoo Taheri

Gastroenterology Fargo, ND Medical Doctor

NPI 1215917992 CMS profile 190625

2301 25Th St S, Ste I, Fargo, ND 58103

Open in the dashboard

General payments

$28,309

55 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$179,380 paid to institutions, not to them · program years 2019–2021

Through program year 2021, Arezoo Taheri of Fargo, ND is reported in the CMS Open Payments database as having received $28,309 across 55 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $179,380 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $20 1
2020 General $8,890 12
2019 General $19,400 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arezoo Taheri
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Arezoo Taheri were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Arezoo Taheri Gastroenterology median Middle half National median
2019 $19,400 $417 $126–$1,100 $163
2020 $8,890 $224 $74–$624 $114
2021 $20 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Pfizer Inc. $28,004 36 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $223 14 payments
  3. Intercept Pharmaceuticals, Inc. $37 2 payments
  4. Janssen Biotech, Inc. $30 2 payments
  5. AbbVie, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,650 6 payments
  2. Travel and Lodging $7,868 15 payments
  3. Consulting Fee $3,750 1 payment
  4. Food and Beverage $1,041 33 payments
Products named General payments · program years 2019–2021
  1. XELJANZ $28,004 36 payments
  2. Entyvio Lower GI $149 9 payments
  3. ENTYVIO Internal Medicine $71 4 payments
  4. STELARA $30 2 payments
  5. INFLECTRA $21 1 payment
  6. OCALIVA $20 1 payment
  7. SIMPONI $18 1 payment
  8. HUMIRA $14 1 payment
  9. Dexilant $3 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

500

Median for Gastroenterology: 569

Drug cost

$10,932

Median for Gastroenterology: $104,976

Branded share of claims

79%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 84 $5,286
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 185 $2,799
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 126 $2,020
Pantoprazole Sodium Generic 87 $575
Omeprazole Generic 18 $253

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$51,581

Medicare's payments for the services billed

Medicare patients

342

Average age 72

Services billed

464

181 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 49%
Depression 26%
Diabetes 22%
Chronic kidney disease 22%
Ischemic heart disease 21%
Atrial fibrillation 18%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record